Expand AMGN Menu
AMGN MENU

AMGN Latest Press Releases

-- November 26, 2024 --

AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDY PRNewswire 7:05 AM
AMGEN TO HOST WEBCAST TO DISCUSS MARITIDE PHASE 2 RESULTS AND PROGRESS ON DEVELOPMENT PROGRAM PRNewswire 7:00 AM

-- November 20, 2024 --

AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT PRNewswire 4:00 PM

-- November 15, 2024 --

AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm Globe Newswire 9:00 PM

-- November 14, 2024 --

AMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024 PRNewswire 4:00 PM

-- November 13, 2024 --

MOORE LAW ENCOURAGES AMGEN INC. INVESTORS TO CONTACT LAW FIRM PRNewswire 3:27 PM
AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA PRNewswire 5:00 AM

-- November 8, 2024 --

AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE PRNewswire 4:00 PM
TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS PRNewswire 2:00 AM

-- October 30, 2024 --

AMGEN REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS PRNewswire 4:01 PM

-- October 25, 2024 --

AMGEN ANNOUNCES 2024 FOURTH QUARTER DIVIDEND PRNewswire 4:00 PM

-- October 24, 2024 --

AMGEN ANNOUNCES WEBCAST OF 2024 THIRD QUARTER FINANCIAL RESULTS PRNewswire 4:00 PM

-- October 15, 2024 --

AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024 PRNewswire 8:00 AM

-- October 1, 2024 --

LA LA ANTHONY PARTNERS WITH AMGEN TO SHARE CANDID, BEHIND-THE-SCENES LOOK AT HOW PLAQUE PSORIASIS AFFECTS HER LIFE PRNewswire 9:00 AM

-- September 30, 2024 --

NASDAQ: AMGN Lawsuit Notice: Investors in shares of Amgen Inc. (NASDAQ: AMGN) should contact the Shareholders Foundation PRNewswire 10:30 AM

-- September 24, 2024 --

TEPEZZA (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASE PRNewswire 4:00 PM

-- September 23, 2024 --

AMGEN TO HOST CONFERENCE CALL TO DISCUSS NEW TOPLINE DATA IN INFLAMMATION AND RARE DISEASE PRNewswire 4:00 PM

-- September 13, 2024 --

AMGEN TO PRESENT DATA FROM MULTIPLE EARLY-STAGE CLINICAL TRIALS AT ESMO 2024 PRNewswire 9:00 AM

-- September 9, 2024 --

AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA (TARLATAMAB-DLLE) IN SMALL CELL LUNG CANCER AT WCLC 2024 PRNewswire 9:00 AM

-- August 30, 2024 --

AMGEN TO PRESENT AT THE 2024 WELLS FARGO HEALTHCARE CONFERENCE PRNewswire 4:00 PM

-- August 29, 2024 --

AMGEN TO PRESENT AT THE MORGAN STANLEY 22ND ANNUAL GLOBAL HEALTHCARE CONFERENCE PRNewswire 4:00 PM

-- August 20, 2024 --

OTEZLA (APREMILAST) NOW AVAILABLE IN THE U.S. FOR MODERATE TO SEVERE PEDIATRIC PLAQUE PSORIASIS PRNewswire 9:00 AM

-- August 6, 2024 --

AMGEN REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS PRNewswire 4:01 PM
Ligand Reports Second Quarter 2024 Financial Results Business Wire 4:01 PM

-- August 2, 2024 --

AMGEN ANNOUNCES 2024 THIRD QUARTER DIVIDEND PRNewswire 4:00 PM

-- August 1, 2024 --

AMGEN ANNOUNCES WEBCAST OF 2024 SECOND QUARTER FINANCIAL RESULTS PRNewswire 4:00 PM